Anti‐amyloid antibodies in Europe: Where are we now?
British Journal of Clinical Pharmacology · 2026-06 · 92 (6) · 1533-1535
DOI: 10.1002/bcp.70526 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 11.03.2026. Verfasst von Danica Juricic Nahal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department for Safety and Efficacy Assessment, Agency for Medicinal Products and Medical Devices of Croatia, Zagreb, Croatia. Die Arbeit nennt 11 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department for Safety and Efficacy Assessment, Agency for Medicinal Products and Medical Devices of Croatia, Zagreb, Croatia.
- University Hospital Centre Zagreb, Zagreb, Croatia.
ORCID-Profile: Ivana Cegec
Zitieren
APA
Juricic Nahal, D., Mas, P., Cegec, I., Bego, M., & Domjanovic, I. K. (2026). Anti‐amyloid antibodies in Europe: Where are we now?. British Journal of Clinical Pharmacology, 92(6), 1533-1535. https://doi.org/10.1002/bcp.70526
Vancouver
Juricic Nahal D, Mas P, Cegec I, Bego M, Domjanovic IK. Anti‐amyloid antibodies in Europe: Where are we now?. British Journal of Clinical Pharmacology. 2026;92(6):1533-1535. doi:10.1002/bcp.70526
BibTeX
@article{JuricicNahal2026,
author = {Juricic Nahal, Danica and Mas, Petar and Cegec, Ivana and Bego, Margareta and Domjanovic, Iva Klarica},
title = {Anti‐amyloid antibodies in Europe: Where are we now?},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
volume = {92},
number = {6},
pages = {1533--1535},
doi = {10.1002/bcp.70526}
}
EUVIMED